Ade LLC Increases Stake in Amgen Inc. $AMGN

Ade LLC grew its position in Amgen Inc. (NASDAQ:AMGN) by 112.6% during the 2nd quarter, Holdings Channel reports. The fund owned 2,551 shares of the medical research company’s stock after buying an additional 1,351 shares during the quarter. Ade LLC’s holdings in Amgen were worth $712,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Prudential PLC increased its position in Amgen by 46.4% during the 2nd quarter. Prudential PLC now owns 40,221 shares of the medical research company’s stock worth $11,230,000 after purchasing an additional 12,743 shares during the period. Lodestone Wealth Management LLC grew its holdings in Amgen by 0.8% during the second quarter. Lodestone Wealth Management LLC now owns 13,304 shares of the medical research company’s stock worth $3,714,000 after acquiring an additional 103 shares during the period. PKS Advisory Services LLC lifted its holdings in Amgen by 2.7% in the second quarter. PKS Advisory Services LLC now owns 1,714 shares of the medical research company’s stock valued at $479,000 after acquiring an additional 45 shares during the period. Athena Investment Management boosted its position in shares of Amgen by 2.1% during the 2nd quarter. Athena Investment Management now owns 3,754 shares of the medical research company’s stock worth $1,048,000 after purchasing an additional 76 shares in the last quarter. Finally, Empirical Finance LLC grew its stake in shares of Amgen by 0.6% during the 2nd quarter. Empirical Finance LLC now owns 18,879 shares of the medical research company’s stock worth $5,271,000 after purchasing an additional 117 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This represents a 11.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares in the company, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.76% of the company’s stock.

Amgen Price Performance

Amgen stock opened at $342.40 on Thursday. The stock has a market capitalization of $184.38 billion, a P/E ratio of 28.00, a P/E/G ratio of 2.61 and a beta of 0.45. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $345.84. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The firm’s 50-day moving average is $298.70 and its two-hundred day moving average is $291.60.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter in the prior year, the firm posted $5.58 earnings per share. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, November 21st. This represents a $9.52 annualized dividend and a dividend yield of 2.8%. Amgen’s dividend payout ratio (DPR) is 73.57%.

Analyst Ratings Changes

AMGN has been the topic of a number of research analyst reports. HSBC boosted their price objective on shares of Amgen from $343.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Scotiabank initiated coverage on Amgen in a report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price objective for the company. DZ Bank upped their target price on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a research report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $319.90.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.